NASDAQ:KROS

Keros Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy KROS

*Your capital is at risk

$10.50

-0.0500 (-0.474%)

At Close: Jun 03, 2026

Keros Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -29.54. In total, the insiders bought 2.43M and sold 2.42M KROS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-29.54
● Buy	2.43M shares
● Sell	2.42M shares
75% Buy Activity Moderate Negative Correlation
Sell Signal Medium Confidence Oct 15, 2025 Analysis Breakdown: Supported by a negative Insider Power Score of -29.54. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 15, 2026 Buy	Common Stock P-Purchase	Bienaime Jean Jacques Director	Director	1 000 Value: $10.6K
Apr 15, 2026 Buy	Common Stock P-Purchase	Bienaime Jean Jacques Director	Director	1 000 Value: $11.7K
Apr 02, 2026 Buy	Employee Stock Option (Right to Buy) M-Exempt	Seehra Jasbir Chief Executive Officer	CEO / President	55 000 Value: $16.5K
Apr 02, 2026 Buy	Common Stock M-Exempt	Seehra Jasbir Chief Executive Officer	CEO / President	55 000 Value: $16.5K
Mar 09, 2026 Buy	Common Stock P-Purchase	Bienaime Jean Jacques Director	Director	2 000 Value: $22.4K
Mar 09, 2026 Buy	Common Stock J-Other	Newton Charles W. Insider	Other	0 Value: $0
Mar 09, 2026 Buy	Common Stock A-Award	Newton Charles W. Director	Director	13 215 Value: $150.0K
Mar 09, 2026 Buy	Stock Option (Right to Buy) A-Award	Newton Charles W. Director	Director	14 788 Value: $167.8K
Feb 24, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Cho Esther Chief Legal Officer	Officer	80 000 Value: $1.24M
Feb 24, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Regnante Keith Chief Financial Officer	C-Suite Officer	60 000 Value: $931.2K
Feb 24, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Seehra Jasbir Chief Executive Officer	CEO / President	217 000 Value: $3.37M
Feb 24, 2026 Buy	Employee Stock Option (right to buy) A-Award	Seehra Jasbir Chief Executive Officer	CEO / President	100 000 Value: $1.55M
Feb 19, 2026 Sell	Common Stock S-Sale	Seehra Jasbir Chief Executive Officer	CEO / President	7 015 Value: $113.4K
Feb 18, 2026 Sell	Common Stock S-Sale	Lerner Lorena Raquel Chief Science Officer	Officer	3 873 Value: $63.3K
Feb 18, 2026 Sell	Common Stock S-Sale	Cho Esther SVP, General Counsel	Officer	4 745 Value: $77.6K
Feb 18, 2026 Sell	Common Stock S-Sale	Regnante Keith Chief Financial Officer	C-Suite Officer	4 739 Value: $77.5K
Jan 07, 2026 Buy	Employee Stock Option (right to buy) A-Award	Seehra Jasbir Chief Executive Officer	CEO / President	62 500 Value: $3.98M
Nov 21, 2025 Sell	Common Stock D-Return	Orbimed Advisors Llc Director	Director	140 057 Value: $2.49M
Nov 21, 2025 Sell	Common Stock D-Return	Orbimed Advisors Llc Director	Director	74 465 Value: $1.32M
Nov 21, 2025 Sell	Common Stock D-Return	Gordon Carl L Director	Director	140 057 Value: $2.49M
Nov 21, 2025 Sell	Common Stock D-Return	Gordon Carl L Director	Director	74 465 Value: $1.32M
Nov 21, 2025 Sell	Common Stock D-Return	Knowles Julius Director	Director	191 527 Value: $3.40M
Nov 21, 2025 Sell	Common Stock D-Return	Knowles Julius Director	Director	130 494 Value: $2.32M
Oct 15, 2025 Sell	Common Stock, $0.0001 par value per share S-Sale	Pontifax Management 4 G.p. (2015) Ltd. 10 Percent Owner	10% Owner	155 262 Value: $2.76M
Oct 15, 2025 Sell	Common Stock S-Sale	Adar1 Capital Management, Llc 10 Percent Owner	10% Owner	743 358 Value: $13.2M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT KEROS THERAPEUTICS INC.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in pat...

Read Full Profile Here